Mucosta

Role

Indications

Reactions

Secondary

Drug Use For Unknown Indication	26.0%
Rheumatoid Arthritis	10.2%
Gastritis	7.8%
Hypertension	6.6%
Depression	5.5%
Product Used For Unknown Indication	4.9%
Prophylaxis	3.9%
Herpes Zoster	3.3%
Nausea	3.2%
Osteoporosis	3.2%
Gastric Ulcer	3.0%
Prophylaxis Against Gastrointestinal Ulcer	3.0%
Oesophagitis	2.9%
Back Pain	2.8%
Osteoarthritis	2.4%
Arthralgia	2.3%
Hyperlipidaemia	2.3%
Sciatica	2.3%
Insomnia	2.3%
Constipation	2.1%

Liver Disorder	16.1%
Thrombocytopenia	8.3%
Interstitial Lung Disease	7.3%
Stevens-johnson Syndrome	6.8%
Vomiting	6.3%
White Blood Cell Count Decreased	6.3%
Hepatic Function Abnormal	5.2%
Sepsis	5.2%
Pyrexia	4.2%
Toxic Epidermal Necrolysis	4.2%
Urticaria	4.2%
Hepatitis Acute	3.6%
Pneumonia Cytomegaloviral	3.6%
Anti-neutrophil Cytoplasmic Antibody Positive Vasculitis	3.1%
Rhabdomyolysis	3.1%
Drug Eruption	2.6%
Drug-induced Liver Injury	2.6%
Hepatitis	2.6%
Somnolence	2.6%
Agranulocytosis	2.1%

Concomitant

Prophylaxis	16.7%
Rheumatoid Arthritis	16.1%
Product Used For Unknown Indication	10.4%
Hypertension	8.0%
Drug Use For Unknown Indication	6.0%
Gastritis	5.5%
Constipation	4.8%
Insomnia	3.9%
Chronic Hepatitis C	3.4%
Hepatitis C	3.4%
Osteoporosis	3.2%
Pain	3.0%
Cancer Pain	2.9%
Multiple Myeloma	2.5%
Diabetes Mellitus	2.1%
Gastritis Prophylaxis	1.8%
Gastric Ulcer	1.7%
Prophylaxis Against Gastrointestinal Ulcer	1.7%
Back Pain	1.6%
Herpes Zoster	1.5%

White Blood Cell Count Decreased	14.4%
Interstitial Lung Disease	10.4%
Vomiting	8.9%
Pyrexia	8.4%
Rash	6.2%
Pneumonia	6.2%
Platelet Count Decreased	5.1%
Hepatic Function Abnormal	4.5%
Liver Disorder	4.1%
Renal Impairment	4.0%
White Blood Cell Count Increased	3.3%
Pneumocystis Jiroveci Pneumonia	3.1%
Sepsis	2.9%
Malaise	2.8%
Thrombocytopenia	2.7%
Stomatitis	2.7%
Renal Failure Acute	2.7%
Rhabdomyolysis	2.6%
Neutrophil Count Decreased	2.5%
Death	2.4%